Diosgenin improves vascular function by increasing aortic eNOS expression, normalize dyslipidemia and ACE activity in chronic renal failure rats
- PMID: 23975507
- DOI: 10.1007/s11010-013-1788-2
Diosgenin improves vascular function by increasing aortic eNOS expression, normalize dyslipidemia and ACE activity in chronic renal failure rats
Abstract
In recent years, the role of endothelial dysfunction (ED) and excessive oxidative stress in the development of cardiovascular diseases has been highlighted. The aim of the present study is to evaluate the effect of diosgenin, an antioxidant on chronic renal failure (CRF) induced vascular dysfunction. CRF was induced by feeding the rats with a diet containing 0.75 % adenine and diosgenin was given orally (everyday at the dose of 40 mg/kg). Isometric force measurement was performed on isolated aortic rings in organ baths. Levels of reduced glutathione (GSH), nitric oxide metabolites, and endothelial nitric oxide synthase mRNA in rat aorta were examined. Further, plasma lipid profile, activity of enzymes of lipid metabolism, and aortic angiotensin converting enzyme (ACE) also studied. The overall results have proved that diosgenin attenuates CRF-induced impairment in acetylcholine induced endothelium-dependent and sodium nitroprusside induced endothelium-independent vascular relaxation. Moreover, it elevates the GSH and restores the eNOS mRNA expression level. CRF-induced dyslipidemia and ACE activity was also inhibited by diosgenin treatment. This study indicates that diosgenin have enough potential to protect vasculature against oxidative stress, dyslipidemia which in turn improves the vascular function in CRF milieu.
Similar articles
-
Diosgenin and Its Analogs: Potential Protective Agents Against Atherosclerosis.Drug Des Devel Ther. 2022 Jul 17;16:2305-2323. doi: 10.2147/DDDT.S368836. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35875677 Free PMC article. Review.
-
Diosgenin interferes coronary vasoconstriction and inhibits osteochondrogenic transdifferentiation of aortic VSMC in CRF rats.Biochimie. 2014 Jul;102:183-7. doi: 10.1016/j.biochi.2014.03.011. Epub 2014 Apr 15. Biochimie. 2014. PMID: 24742379
-
Diosgenin attenuates vascular calcification in chronic renal failure rats.Mol Cell Biochem. 2013 Jun;378(1-2):9-18. doi: 10.1007/s11010-013-1588-8. Epub 2013 Feb 20. Mol Cell Biochem. 2013. PMID: 23423339
-
Phosphate binding reduces aortic angiotensin-converting enzyme and enhances nitric oxide bioactivity in experimental renal insufficiency.Am J Nephrol. 2014;39(5):400-8. doi: 10.1159/000362507. Epub 2014 May 6. Am J Nephrol. 2014. PMID: 24818649
-
Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.Eur J Pharmacol. 2005 Jun 15;516(3):253-9. doi: 10.1016/j.ejphar.2005.04.004. Eur J Pharmacol. 2005. PMID: 15963975
Cited by
-
Chronic treatment of curcumin improves hepatic lipid metabolism and alleviates the renal damage in adenine-induced chronic kidney disease in Sprague-Dawley rats.BMC Nephrol. 2019 Nov 21;20(1):431. doi: 10.1186/s12882-019-1621-6. BMC Nephrol. 2019. PMID: 31752737 Free PMC article.
-
Soluplus-Mediated Diosgenin Amorphous Solid Dispersion with High Solubility and High Stability: Development, Characterization and Oral Bioavailability.Drug Des Devel Ther. 2020 Jul 27;14:2959-2975. doi: 10.2147/DDDT.S253405. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32801637 Free PMC article.
-
Diosgenin and Its Analogs: Potential Protective Agents Against Atherosclerosis.Drug Des Devel Ther. 2022 Jul 17;16:2305-2323. doi: 10.2147/DDDT.S368836. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35875677 Free PMC article. Review.
-
Diosgenin, 4-hydroxyisoleucine, and fiber from fenugreek: mechanisms of actions and potential effects on metabolic syndrome.Adv Nutr. 2015 Mar 13;6(2):189-97. doi: 10.3945/an.114.007807. Print 2015 Mar. Adv Nutr. 2015. PMID: 25770257 Free PMC article. Review.
-
Contribution of Oxidative Stress (OS) in Calcific Aortic Valve Disease (CAVD): From Pathophysiology to Therapeutic Targets.Cells. 2022 Aug 27;11(17):2663. doi: 10.3390/cells11172663. Cells. 2022. PMID: 36078071 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous